Dynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6%
Dynavax Technologies Corporation DVAX was a big mover last session, as the company saw its shares rise almost 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 60% in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Dynavax Technologies currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
Dynavax Technologies Corporation Price
Dynavax Technologies Corporation Price | Dynavax Technologies Corporation Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Aimmune Therapeutics, Inc. AIMT holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is DVAX going up? Or down? Predict to see what others think: Up or Down
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Click for Free Dynavax Technologies Corporation (DVAX) Stock Analysis Report >>
Click for Free Aimmune Therapeutics, Inc. (AIMT) Stock Analysis Report >>
To read this article on Zacks.com click here.
Zacks Investment Research